The research was conducted on the base of Government basic research program No. 0088-2023-0001 Theme "Development of biomedical cell products and creation of a pilot bank of tissue and cell transplants".
On 11 October 2024, the permission of the Ministry of Health of the Russian Federation was obtained to conduct clinical trials of a medicinal product (tissue engineering product) developed at IDB RAS, "Combined Biological Skin Equivalent (CombiBSE) to assess safety and efficacy in the treatment of patients with heat injuries".
This clinical trial of a high-tech drug based on cultured human cells is the second in the Russian Federation.
Akrus BioMed LLC is the industrial platform for the development of drug samples for clinical trials.